NATCO Pharma launches Brivaracetam tablets for epilepsy treatment in India

Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under brand name Briviact®.

Feb 26, 2021 12:02 IST India Infoline News Service

Natco Pharma Limited has announced the launch of Brivaracetam tablets under brand BRECITA in India.

Brivaracetam is indicated towards treatment of epilepsy.

Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under brand name Briviact®.

The Company affirmed that NATCO’s BRECITA tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of INR 25/- and INR 35/- per tablet respectively.

Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.

At around 12:30 PM, Natco Pharma was trading at Rs803.35 per piece up by Rs1.65 or 0.21%  on the BSE.

Related Story

Explore Important Blogs